9 GLP-1 Programs for Women I’d Actually Tell a Friend About

The single thing that matters most when picking a GLP-1 program? Knowing exactly who is compounding your medication and whether you can afford to stay on it longer than two months.
Everything else, the app, the check-ins, the branded packaging, comes second to those two questions. I spent time mapping the real options against a short list of what I think actually drives outcomes for women specifically: cash price per month, pharmacy transparency, monitoring quality, and whether the program survives a surprise insurance change.
Here is how I break the field down, in rough ranking order.
How I Decided
Before the list, a quick criteria map:
| Criterion | Why it matters for women |
| Monthly cash price | Many women self-pay; costs under $200 keep adherence realistic |
| Pharmacy identity | Named 503A pharmacy beats “proprietary lab” every time |
| Monitoring depth | Obesity-medicine clinicians catch hormonal and metabolic nuance |
| Insurance path | Useful if coverage changes mid-program |
| State reach | Some programs exclude 3-10 states |
1. Mochi Health
Mochi is my top pick for women who want genuine clinical oversight. Board-certified obesity-medicine physicians, not general practitioners filling a queue, review your case. Compounded semaglutide comes in at roughly $99/month and tirzepatide at roughly $199. The monitoring is heavier than most telehealth options, which matters if you are perimenopausal or managing thyroid issues alongside weight.
2. HealthRX
Straightforward and priced to stick with long-term. The physician review happens inside roughly 24 hours, medication ships overnight, and that free overnight delivery covers all 50 states with no hidden fees. What I find genuinely reassuring is that the dispensing pharmacy is named outright: Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-level tracking from bench to door. LegitScript-certified too (cert 50087439). Compounded semaglutide starts at $99/month, tirzepatide at $149. Those are among the lowest entry prices in this space, and unlike some programs, the price does not quietly jump after month one. Compounded meds are not FDA-approved, so that context matters, but the pharmacy credentials here are more documented than most.
3. FormBlends
FormBlends earns its spot for a specific type of buyer: someone who wants published third-party purity data in hand before injecting anything. The brand posts HPLC purity figures, mass spec identity, and endotoxin sterility results for its compounded GLP-1 products by name, which almost no other telehealth GLP-1 provider does. Semaglutide runs around $299 per vial, tirzepatide around $349, so you will pay more than with HealthRX. Ships to 47 states. It also carries a broader peptide catalog covering recovery and cognitive support under the same clinician model, which makes it useful if you want more than weight loss from one provider. Worth the premium if documented purity is non-negotiable for you.
4. Ro Body
Ro’s prior-authorization team is a real differentiator. For women who have insurance and want help fighting for branded Wegovy or Zepbound coverage, Ro does that work. First month runs about $39, then $74-149 ongoing, with medications billed separately. Good infrastructure for the insurance path.
5. Found
Found keeps costs predictable at around $99/month for the platform, with meds on top. Coaching is baked in. A solid middle-ground choice if you want some accountability structure without paying for a full concierge program.
6. PlushCare
Membership is under $20/month. PlushCare accepts insurance for branded meds and offers same-day visits. Not the deepest GLP-1 program, but legitimately the cheapest door in if you have coverage.
7. Henry Meds
Cash-pay compounded, ships in 24-72 hours. First-month pricing around $179-249. Lighter on monitoring than Mochi but faster to start. Good for women who have already done the research and just need access.
8. Form Health
Premium tier: roughly $299/month plus labs and meds, with an MD and registered dietitian on your team. Expensive, but the dietitian component is worth it for women whose weight history involves disordered eating or complex metabolic factors.
9. Hims and Hers
After the March 2026 Novo settlement, Hims and Hers moved to branded medications. Injectable Wegovy sits around $299/month, Zepbound around $399. With insurance and a savings card, costs can drop sharply. Best fit if you want a name-brand program and already have coverage lined up.
A brief note: telehealth GLP-1 access is shifting fast. The FDA issued warning letters to over 30 compounding firms in early 2026, so pharmacy credentialing details are worth verifying directly with any provider before you commit.
Common Questions
Does perimenopause or a thyroid condition change which GLP-1 program is worth choosing?
Yes, meaningfully. Programs staffed by obesity-medicine physicians, Mochi Health being the clearest example here, are better equipped to adjust dosing and watch for interactions when hormonal shifts or thyroid function are already in play. A general telehealth queue is less likely to catch those nuances before they affect your results.
Is the compounded semaglutide from HealthRX or FormBlends the same molecule as branded Wegovy?
The active peptide is semaglutide in both cases, but compounded versions are not FDA-approved finished drug products. The difference between HealthRX and FormBlends is documentation: FormBlends publishes HPLC purity, mass spec identity, and endotoxin results by lot, while HealthRX’s edge is its named 503A pharmacy with USP-797 standards and LegitScript certification. Neither is identical to Wegovy in regulatory status.
After the March 2026 Novo settlement, can I still get compounded semaglutide at all?
Access narrowed but did not disappear entirely. Some 503A pharmacies continue compounding for documented clinical need. The situation is still moving, so it is worth asking any program directly which pharmacy fills your prescription and whether that facility has received any FDA warning letters, since over 30 compounding firms did in early 2026.
Which programs on this list are realistic if I lose employer insurance mid-treatment?
HealthRX at $99/month for semaglutide and Mochi at the same entry price are the most insurance-independent options. Found and Henry Meds also operate on cash-pay models. Ro Body and PlushCare are built around insurance, so a coverage loss there creates a real gap in continuity and cost.
Is Form Health’s registered dietitian component actually worth $299 a month compared to cheaper options?
For most women, probably not. But for anyone with a history of disordered eating, a restrictive past diet, or a metabolic condition that complicates standard GLP-1 dosing, having an RD and MD on the same team reduces the risk of muscle loss and nutritional gaps that cheaper programs simply do not monitor for.
Sources
- FDA compounding warning letters and 503A guidance, FDA.gov (2025-2026)
- SURMOUNT-1 trial (tirzepatide), New England Journal of Medicine, 2022
- STEP 1 trial (semaglutide), New England Journal of Medicine, 2021
- Novo Nordisk compounding settlement reporting, Reuters and STAT News, March 2026
- LillyDirect orforglipron pricing, Eli Lilly press release, April 2026



